|Chemical and physical data|
|Molar mass||414.622 g/mol g·mol−1|
|3D model (JSmol)|
|(what is this?)|
O-1812 is an eicosanoid derivative related to anandamide that acts as a potent and highly selective agonist for the cannabinoid receptor CB1, with a Ki of 3.4 nM at CB1 and 3870 nM at CB2. Unlike most related compounds, O-1812 is metabolically stable against rapid breakdown by enzymes, and produces a cannabinoid-like discriminative effect in rats, which is similar but not identical to that produced by cannabinoid drugs of other chemical classes.
- Di Marzo V, et al. (February 2001). "Highly selective CB1 cannabinoid receptor ligands and novel CB1/VR1 vanilloid receptor "hybrid" ligands". Biochemical and Biophysical Research Communications. 281 (2): 444–51. doi:10.1006/bbrc.2001.4354. PMID 11181068.
- Baskfield CY, Martin BR, Wiley JL (April 2004). "Differential effects of Δ9-tetrahydrocannabinol and methanandamide in CB1 knockout and wild-type mice". The Journal of Pharmacology and Experimental Therapeutics. 309 (1): 86–91. doi:10.1124/jpet.103.055376. PMID 14718593.
- Wiley JL, et al. (August 2004). "A comparison of the discriminative stimulus effects of Δ9-tetrahydrocannabinol and O-1812, a potent and metabolically stable anandamide analog, in rats". Experimental and Clinical Psychopharmacology. 12 (3): 173–9. doi:10.1037/1064-12188.8.131.52. PMID 15301634.
- Wiley JL, Smith FL, Razdan RK, Dewey WL (March 2005). "Task specificity of cross-tolerance between Δ9-tetrahydrocannabinol and anandamide analogs in mice". European Journal of Pharmacology. 510 (1–2): 59–68. doi:10.1016/j.ejphar.2005.01.006. PMID 15740725.
- Breivogel CS, et al. (July 2008). "Sensitivity to Δ9-tetrahydrocannabinol is selectively enhanced in β-arrestin2 -/- mice". Behavioural Pharmacology. 19 (4): 298–307. doi:10.1097/FBP.0b013e328308f1e6. PMC 2751575. PMID 18622177.